Vascular endothelial growth factor signaling in acute myeloid leukemia (Q38029546)

27 August 2017

Vascular endothelial growth factor signaling in acute myeloid leukemia (English)

1 reference

27 August 2017

0 references

1 reference

1

Kim R Kampen

1 reference

27 August 2017

Arja Ter Elst

2

1 reference

PubMed ID

22833169

27 August 2017

Eveline S J M de Bont

series ordinal

3

1 reference

27 August 2017

26 July 2012

1 reference

Cellular and Molecular Life Sciences

27 August 2017

1 reference

27 August 2017

70

1 reference

27 August 2017

8

1 reference

27 August 2017

1307-1317

1 reference

https://scigraph.springernature.com/pub.10.1007/s00018-012-1085-3

27 August 2017

0 references

cites work

Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Independent prognostic factors for AML outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

The biology of vascular endothelial growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Phosphorylated KDR can be located in the nucleus of neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

The role of VEGF and a functional link between VEGF and p27Kip1 in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular Endothelial Growth Factor A isoform mRNA expression in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Identifying causal rare variants of disease through family-based analysis of Genetics Analysis Workshop 17 data set

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Genetic association of angiogenesis- and hypoxia-related gene polymorphisms with osteonecrosis of the femoral head

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular endothelial growth factor and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

High acute myeloid leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Stem cells find their niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Bone-marrow haematopoietic-stem-cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Human mesenchymal stem cells as a stable source of VEGF-producing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

STAT3 mediates bone marrow mesenchymal stem cell VEGF production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-012-1085-3

MRC trials in childhood acute myeloid leukaemia

21 January 2018

1 reference

12 December 2020

Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients

1 reference

12 December 2020

Bone marrow microvessel density and its prognostic significance in AML

1 reference

12 December 2020

Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice

1 reference

12 December 2020

Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)-acute myeloid leukemia 10 modified protocol

1 reference

12 December 2020

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

1 reference

12 December 2020

Evidence of increased angiogenesis in patients with acute myeloid leukemia

1 reference

12 December 2020

Plasma vascular endothelial growth Factor-A (VEGF-A) and VEGF-A gene polymorphism are associated with hydrocele development in lymphatic filariasis.

1 reference

12 December 2020

Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate

1 reference

12 December 2020

Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia

1 reference

12 December 2020

Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts

1 reference

12 December 2020

Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients

1 reference

12 December 2020

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Bone marrow long label-retaining cells reside in the sinusoidal hypoxic niche

1 reference

12 December 2020

VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer

1 reference

12 December 2020

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

1 reference

12 December 2020

Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia

1 reference

12 December 2020

Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor

1 reference

12 December 2020

Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter

1 reference

12 December 2020

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

1 reference

12 December 2020

Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia

1 reference

12 December 2020

Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity

1 reference

12 December 2020

10.1007/S00018-012-1085-3

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22833169